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Abstract
OBJECTIVES: The aims of this study were to evaluate the inﬂuence of cardiopulmonary bypass (CPB) on the plasma concentrations and
pharmacokinetics of cefuroxime and to assess whether the cefuroxime dose regimen (a 1.5 g dose, followed by 750 mg every 6 h for
24 h) is adequate for cardiac surgery antibiotic prophylaxis.
METHODS: A prospective, controlled, observational study compared patients undergoing coronary surgery with CPB (CPB group,
n = 10) or off-pump surgery (off-pump group, n = 9). After each cefuroxime dose, blood samples were sequentially collected and
analysed using high-efﬁciency chromatography. For demographic data and pharmacokinetic parameters, the authors used Fisher’s exact
test for nominal variables and Student’s t-test and the Mann–Whitney U-test for parametric and non-parametric variables, respectively.
Plasma concentrations were compared using ANOVA, and the percentage of patients with a remaining plasma concentration of >16
mg/l within 6 h after each bolus was quantiﬁed in tabular form.
RESULTS: After each cefuroxime bolus was administered, both groups presented a signiﬁcant decrease in plasma concentration over
time (P < 0.001), without differences between the groups. The mean CPB time of 59.7 ± 21.1 min did not change cefuroxime plasma
concentrations or pharmacokinetics. The mean clearance ± SD (ml/kg/min) and median elimination half-life (h) of the CPB group versus
the off-pump group were 1.7 ± 0.7 versus 1.6 ± 0.6 (P = 0.67), respectively, and 2.2 versus 2.3 (P = 0.49), respectively. Up to 3 h following
the ﬁrst bolus of 1.5 g, but not after 6 h, all patients had plasma concentrations >16 mg/l (CPB group = 20% and off-pump group = 44%).
However, after all 750 mg boluses were administered, concentrations <16 mg/dl were reached within 3 h.
CONCLUSIONS: CPB does not inﬂuence cefuroxime plasma concentrations. The dosing regimen is adequate for the intraoperative
period, but in the immediate postoperative period, it requires further review.
Keywords: Cefuroxime • Pharmacokinetics • Cardiac surgery • Cardiopulmonary bypass • HPLC
INTRODUCTION
In cardiac surgery, postoperative surgical site infection and med-
iastinitis are serious complications, with incidences ranging from
1.9 to 15%, especially for lower limb infections [1, 2]. The institu-
tion of cardiopulmonary bypass (CPB) in cardiac surgery, which
promotes extensive haemodilution and physiological changes,
has had profound effects on the plasma concentration of drugs
and, therefore, on their therapeutic effectiveness, which presents
an additional risk because these effects can alter antibiotic
pharmacokinetics [3, 4].
Postoperative infections can increase morbidity, mortality and
their associated costs in both man-hours and dollars spent;
therefore, it is important to evaluate existing standards for the
prevention and management of nosocomial infection and ﬁnd
optimal strategies for best practice implementation [5, 6]. When
trying to prevent nosocomial infection, prophylactic intravenous
antibiotics should be routinely administered to patients under-
going cardiac surgery [7]. The cephalosporin class of antimicro-
bials is currently the ﬁrst choice for prophylaxis of infection from
coronary operations, and the glycopeptides are selected for
allergic patients or for centres with a high prevalence of
methicillin-resistant Staphylococcus aureus [8, 9]. There has been
a trend towards superior efﬁcacy with cefuroxime compared
with the other cephalosporins, but this difference has not
reached statistical signiﬁcance [7, 10, 11]. However, the prophy-
lactic cefuroxime dose regimen previously studied (1.5 g bolus
followed by 1.5 g every 12 h for 24 h) is not ideal because the
washout of cefuroxime is completed before the 12th hour [12].
In β-lactam antibiotic prophylaxis, the time at which plasma con-
centrations remain above the minimal inhibitory concentration
(MIC) is more important than the maximum concentrations that
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are reached [12, 13], and it is necessary to consider the local
bacteriological proﬁle when choosing a cephalosporin.
Cefuroxime has a low toxicity and cost and good tissue penetra-
tion. Moreover, it has a good spectrum of activity against bacteria
that often cause postoperative infections [7]. However, for patients
undergoing cardiac surgery with CPB, there is no consensus on the
ideal dose of cefuroxime to prevent infection [12, 14–21].
The MIC of cefuroxime ranges from 1 to 4 mg/l for the princi-
pal bacteria that are involved in surgical site infections.
Maintenance concentrations of four times greater than the MIC
are recommended as an alternative to protect patients against
infections that are caused by more resistant bacterial strains. The
presence of the drug at this concentration allows for adequate
prophylaxis during cardiac surgery [13, 15].
The main goals of this study were to evaluate whether CPB
inﬂuences the plasma concentrations and pharmacokinetics of
cefuroxime and whether the dosing regimen of a 1.5 g bolus at
the induction of anaesthesia, followed by three boluses of 750
mg every 6 h (total dose = 3.75 g), is adequate to maintain
plasma concentrations >16 mg/l for the ﬁrst 24 h after the begin-
ning of surgery.
METHODS
Patients and clinical procedure
After approval from the Hospital Ethics Committee (identiﬁer:
123/06), registration on ClinicalTrials.gov (identiﬁer: NCT
01228825) and obtaining written informed consent from each
individual, 20 patients who were scheduled for coronary artery
bypass graft surgery (CABG) were enrolled in the study. The
exclusion criteria included age over 75 years old, a body mass
index (BMI) of >35 kg/m2, a left ventricle ejection fraction <35%,
previous nephrectomy, serum creatinine ≥1.4 mg/dl, prothrom-
bin activity lower than 80% and use of oral anticoagulants or al-
lergies to cefuroxime.
The patients were allocated to two groups: CABG with CPB
(CPB group, n = 10) and without CPB (off-pump group, n = 9).
The choice of the groups was performed in an independent
manner because the decision to utilize CPB depended on the
position of the anastomosed arteries and the choice of the surgi-
cal team. Cefuroxime (ZinacefR, Lot: 6043, GlaxoSmithKline
Brazil, Ltd, Rio de Janeiro, Brazil) was administered intravenously
in a bolus dose of 1.5 g at the induction of anaesthesia at least
30 min before the chest incision, followed by three boluses of
750 mg every 6 h for 24 h (total dose = 3.75 g).
CPB without concentrators or ultra-ﬁltrating devices was per-
formed using an extracorporeal circuit and a membrane oxygen-
ator, primed with lactated Ringer’s solution (Oxim II-34 Ultra
membrane oxygenator Edwards Lifesciences, Irvine, CA, USA).
After the initiation of CPB, the patients were cooled, and the
core temperature was maintained at 28–34°C until the end of
coronary grafting. After rewarming to 37°C, the patients were
weaned from CPB. When necessary, vasoactive drugs were
infused by the attending anaesthesiologist.
Analytical procedure
After the ﬁrst bolus of cefuroxime, blood samples were drawn
from a radial catheter every 15 min of the ﬁrst hour and at 2, 3
and 6 h. Extra samples were also collected at periods considered
as having high risk for bacterial contamination: at chest incision,
at the beginning of CPB (or the beginning of anastomosis for the
off-pump group), after protamine infusion and at chest suture.
For the additional bolus, samples were collected after 30 min
and at 1, 3 and 6 h.
The blood samples were centrifuged at 3000 rpm for 20 min,
and plasma was frozen and stored at −20°C until analysis. The
HPLC method was used to determine plasma cefuroxime con-
centrations and was validated before the protocol [12, 22].
The kinetic disposition of cefuroxime was evaluated by apply-
ing the open monocompartmental model, which is based on
plasma drug concentrations multiplied by time (C × T), after the
last bolus of cefuroxime. PK Solutions software, version 2.0, by
Monocompartment Pharmacokinetics Data Analysis (Ashland,
OH, USA), was used to perform this modelling.
The groups were also compared according to the length of
surgery, the number of grafts, temperature, blood pressure,
haematocrit, total diuresis, crystalloid volume and the quantity of
red blood cells received.
To calculate the sample size, it was assumed that CPB could
change cefuroxime plasma concentrations by 20%, with a 10%
standard deviation (SD); there was one control for each case. An
unpaired Student’s t-test was used with 80% power and an α
error of 5%, which resulted in a minimum sample size of six
cases and six controls, with 10 degrees of freedom.
All data were tested for normality using the Shapiro–Wilk test.
For demographic data and pharmacokinetic parameters, the
authors used Fisher’s exact test for nominal variables and
Student’s t-test and the Mann–Whitney U-test for parametric
and non-parametric variables, respectively. ANOVA was used to
evaluate the haematocrit values and for the comparison of
cefuroxime plasma concentrations after the logarithmic trans-
formation of non-parametric variables to parametric variables.
Time was a covariate when necessary (e.g. samples collected at
periods of high risk for bacterial contamination).
For each group, the percentage of patients with remaining
plasma concentrations >16 mg/l within 6 h after each bolus was
illustrated in tabular form.
RESULTS
One patient in the off-pump group was excluded because the
installation of CPB was necessary during the procedure. Table 1
shows the baseline characteristics of the patients and the pre-
operative and surgical data for both groups. The mean length of
CPB was 59.7 ± 21.1 min, which took into account that this group
was submitted to a minimum haematocrit and to lower tem-
peratures than the off-pump group. The lowest values of mean
arterial pressure in the CPB group were observed immediately
after the beginning of bypass, but they normalized within a few
seconds. The CPB group also had a greater number of grafts,
with no difference in surgical time. No patient presented with
surgical site infection until discharge from the hospital, and the
patients had been in the intensive care unit for a maximum
period of 3 days without complications.
After each dose of cefuroxime, both groups presented ﬁrst an
increase and then a signiﬁcant decrease in drug plasma concen-
trations over time (P < 0.001), without a signiﬁcant difference
between groups (Fig. 1).
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Table 2 shows the mean concentrations and the 95% CI of
both groups during critical moments of antimicrobial prophy-
laxis, which were comparable between the groups (P = 0.218).
The results of the pharmacokinetic data of cefuroxime after the
last bolus of cefuroxime showed no differences between the
groups (Table 3).
Evaluating the dosing regimen, Fig. 1 shows that the mean
cefuroxime plasma concentrations were greater than four
times the MIC until 3 h after each bolus, except for the third bolus
in the off-pump group and the fourth bolus in the CPB group; for
the ﬁrst cefuroxime dose (1.5 g), all patients had plasma concen-
trations that were more than four times the MIC until 3 h after the
bolus. However, immediately before the second dose, only 20%
of the patients from the CPB group and 44% of the patients from
the off-pump group presented concentrations greater than this
desired value. After each bolus of 750 mg, both groups reached
cefuroxime plasma concentrations that were less than four times
the MIC before 3 h had passed (Table 4).
Table 1: Comparison of baseline characteristics and preoperative and intraoperative data of CPB and off-pump groups
Variable CPB group (n = 10) Off-pump group (n = 9) P-value
Mean (SD) or median 95% CI or Q1, Q3 Mean (SD) or median 95% CI or Q1, Q3
Baseline characteristics
Age (years)* 59.3 (9.1) 52.8–6.8 59.6 (6.9) 54.2–64.9 0.95
Weight (kg)* 68.4 (8.3) 62.5–74.3 76.6 (11.3) 69.9–85.2 0.09
Height (m)* 1.6 (0.1) 1.6–1.7 1.7 (0.1) 1.6–1.8 0.28
BMI (kg/m2) * 25.6 (2.8) 23.6–27.6 27.3 (3.1) 24.8–29.7 0.24
Gender (number)**
Male 6 5 0.99
Female 4 4
Preoperative data
Urea (mg/dl)* 29.8 (7.7) 24.3–35.3 34.3 (6.2) 29.6–39.1 0.18
Creatinine (mg/dl)* 0.9 (0.17) 0.8–1.1 1.0 (0.1) 0.9–1.1 0.10
Calculated creatinine clearance (ml/min)* 89.2 (26.8) 70.0–108.3 80.8 (17.3) 67.5–94.2 0.44
Glycaemia (mg/dl)* 105.6 (26.9) 86.4–124.8 115.1 (27.1) 94.3–135.9 0.45
Prothrombin activity (%)*** 95 83.1, 100.0 81.8 77.0, 100.0 0.62
Intraoperative data
Length of surgery (min)*** 129.9 116, 142 130 127, 133 0.46
Haematocrit (%)**** <0.001
Initial 40.3 (3.8) 37.4–43.1 37.8 (3.9) 34.8–40.8 0.19
Minimum 23.4 (3.2) 21.0–25.9 28.7 (5.6) 24.4–33.0 0.03
Final 27.3 (2.5) 25.4–29.3 31.3 (6.0) 26.7–35.8 0.09
Red blood transfusion (units)*** 1 1, 2 1 0, 2 1.0
Number of grafts*** 4 3, 5 2 1, 3 0.002
Minimum blood pressure (mmHg)*** 39.5 32.5–46.5 57.8 52.7–62.9 <0.001
Minimum temperature (°C)*** 30 29, 31 35 34, 35 <0.001
Diuresis (ml)*** 725 600, 900 700 600, 800 0.62
Volume replacement (ml)* 3542 (748.6) 2576–4327 3611 (546.5) 3191–4035 0.29
Parametric variables: mean (SD) and 95% CI used as summary measures, comparisons by Student’s t-test (*) or ANOVA (****). Nominal variable: Fischer’s
exact test (**). Non-parametric variables: median and 1°, 3° inter-quartile, comparisons by the Mann–Whitney test (***), P < 0.05.
Figure 1: Plasma curve decay for the concentrations of cefuroxime in a 24-h period. The values are reported as the mean ± 1 SD. Filled circles: CPB group; open
circles and dashed line: off-pump group. Comparisons by ANOVA, P < 0.05.
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DISCUSSION
The results showed that CPB with an average time of 59.7 ± 21.1
min and a minimal mean temperature of 29.9 ± 1.3°C did not in-
ﬂuence plasma concentrations or cefuroxime kinetics, and an
extra bolus of cefuroxime after CPB was unnecessary. The dosing
regimen used in our study guaranteed plasma concentrations
that were more than four times the MIC during the intraopera-
tive period, but during all other intervals between doses, the
dosing regimen should be reviewed.
CPB can promote a drop in drug plasma concentrations due
to haemodilution, changes in the volume of distribution, a redis-
tribution of blood ﬂow to peripheral tissue, vasodilatation, in-
ﬂammatory activity, drug sequestration by the CPB circuit and
lungs, and decreased protein binding, especially in procedures
that last longer than 400 min. Therefore, some authors have jus-
tiﬁed using an extra bolus of antibiotic at the end of CPB to
avoid inadequate serum antibiotic levels at the time of clot for-
mation [3, 4, 20]. We found that cefuroxime plasma concentra-
tions decreased during the ﬁrst minutes of CPB, which was
similar to the ﬁndings of these authors, but this decrease
promptly recovered in the next few minutes (Table 2).
Our study and others showed that CPB did not exert inﬂuence
on water-soluble cephalosporins, especially if the patients were
submitted to moderate hypothermia or if the CPB lasted <120
min [12, 17, 18, 23]. The rate of elimination of the water-soluble
cephalosporins is dependent on renal function, which is changed
by CPB [4, 12, 17, 23]. Hypothermia, hypotension, changes from
pulsatile to non-pulsatile ﬂow and changes in protein binding can
reduce the plasma clearance, prolong the biological half-life and
elevate plasma concentrations, making the extra dose unneces-
sary [18]. However, plasma concentrations or pharmacokinetics of
vancomycin, a water-soluble glycopeptide antibiotic 90%
excreted unchanged by the kidney, are not inﬂuenced by the use
of profound hypothermic circulatory arrest [24].
Despite the various conclusions of different dosing regimens,
previous studies have found no concrete justiﬁcation for the ad-
ministration of an extra bolus based on the use of CPB [12, 17,
18, 20, 23], and the results of this study indicated that antibiotic
prophylaxis should be performed at ﬁxed intervals according to
the pharmacokinetics of the antibiotic, rather than according to
the use of CPB.
Cefuroxime, as reported before [12, 17], showed linear
pharmacokinetics; in addition, we did not ﬁnd differences either
in pharmacokinetic parameters between groups or in cefuroxime
plasma concentrations after each antibiotic bolus, and during
critical moments for antibiotic prophylaxis, we observed that
more patients in the off-pump group had cefuroxime plasma
concentrations >16 mg/dl at 6 h after the ﬁrst dose (Table 4).
The sample size was calculated considering cefuroxime plasma
concentrations, and it could have been underpowered to detect
differences in pharmacokinetic parameters. The kinetic dispos-
ition of cefuroxime was evaluated only after the last dose of
cefuroxime, when the effect of CPB could have been less
evident, but differences in the pharmacokinetic parameters were
not found when other authors compared cefuroxime pharmaco-
kinetic parameters after each bolus, only in patients who were
not submitted to CPB [17].
There are many schemes for antibiotic prophylaxis in patients
undergoing cardiac surgery with CPB, with variations in the
intervals between doses and/or in the duration of prophylaxis
[12, 14–19, 21]. However, plasma concentrations of at least four
times the MIC must be reached and maintained throughout the
intraoperative period, which encompasses the greatest risk for
bacterial contamination, for effective antibiotic prophylaxis [13].
As demonstrated by Nascimento et al. [12], a dosing regimen
of 1.5 g every 12 h for 24 h is ineffective for guaranteeing
plasma concentrations greater than four times the MIC.
In the present study (cefuroxime dose regimen of a 1.5 g
bolus and then 750 mg every 6 h for 24 h), all patients had
plasma concentrations greater than four times the MIC until 3 h
after the ﬁrst bolus of 1.5 g. Considering that the length of
surgery was <3 h in both groups and that, during critical periods
Table 2: Cefuroxime plasma concentrations (mg/l)
during critical periods for antibiotic prophylaxis
Blood samples CPB group Off-pump group
Mean (SD) 95% CI Mean (SD) 95% CI
Chest incision 63.1 (19.9) 45.4–80.7 76.6 (57.7) 19.3–133.9
Beginning CPB/
anastomosis
27.4 (7.5) 20.8–34.0 57.7 (34.0) 23.9–91.5
After protamine 30.0 (6.5) 24.3–35.8 38.5 (24.7) 13.9–63.0
Chest suture 25.7 (7.0) 19.5–32.0 25.8 (19.3) 6.7–45.0
Mean (SD) and 95% CI used as summary measures.
Table 3: Pharmacokinetic parameters and statistical analysis between CPB and off-pump groups
Variable CPB group Off-pump group P-value
Mean (SD) or median 95% CI or Q1, Q3 Mean (SD) or median 95% CI or Q1, Q3
Minimum concentration (mg/l)* 6.1 4, 7.7 5.7 4.6, 9.1 0.77
AUC 18–24 h (mg h/l)* 118.7 89.4, 141.4 120.7 91.3, 128.9 0.97
Elimination half-life (h)* 2.2 1.9, 2.5 2.3 2.1, 3.4 0.49
Elimination constant (h−1)** 0.3 (0.1) 0.3–0.4 0.3 (0.1) 0.2–0.4 0.35
Volume of distribution (l/kg)** 0.3 (0.1) 0.2–0.4 0.4 (0.2) 0.2–0.5 0.70
Clearance (ml/kg/min)** 1.7 (0.7) 1.2–2.2 1.6 (0.6) 1.1–2.0 0.67
Non-parametric variables: median and 1°, 3° inter-quartile, comparisons by the Mann–Whitney test (*). Parametric variables: mean and 95% CI used as
summary measures, comparisons by Student’s t-test (**), P < 0.05.
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of antibiotic prophylaxis, all mean plasma concentration were
also >16 mg/dl, there was no need for an extra dose after CPB,
and this antibiotic regimen was adequate for the intraoperative
period. However, the doses of 750 mg of cefuroxime used for
the second, third and fourth boluses were not sufﬁcient to guar-
antee the desirable plasma concentrations until the sixth hour.
Considering the real possibility of complicated and long-length
cases of cardiac surgery, using or not using CPB, the second
dose might not be sufﬁcient to maintain plasma concentrations
>16 mg/dl until chest closure. Although recent trends have
favoured only intraoperative coverage, the data are not yet con-
clusive for patients undergoing cardiac surgery, so single-dose
prophylaxis could be used in circumstances the surgeon consid-
ers optimal for patient care (Class IIa, Level B) [14], but it is also
necessary to consider the surgical time.
Regarding the length of the dosing regimen, there is evidence
indicating that antibiotic prophylaxis of 48 h is as effective as a
24-h regimen (Class IIa, Level B) [14], but an inadequate drug
type and/or dosage regimen can create antibiotic-resistant
microorganisms [7]. The 24-h dosing regimen that was used in
this study showed that the mean cefuroxime plasma concentra-
tion was greater than four times the MIC until 3 h after each
bolus, except for the third bolus in the off-pump group and the
fourth bolus in the CPB group, but they were all greater than the
MIC, without differences between the groups (Fig. 1). Moreover,
6 h after each bolus, the number of patients with cefuroxime
plasma concentrations greater than four times the MIC was very
low, indicating the need to shorten the dose interval (Table 4).
The observed mean cefuroxime half-lives were 2.2 and 2.3 h
for the CPB and off-pump groups, respectively (Table 3). A short-
ening of the interval between doses from 6 to 4 h, instead of the
use of larger doses at longer intervals, could be a more effective
dosing regimen for patients undergoing cardiac surgery with
CPB lasting <2 h.
It is important to consider that when we propose changes to
the interval between doses, we are elevating the total dose of
cefuroxime; however, this dose is the same as that recom-
mended by American Heart Association’s and American College
of Cardiology’s AHA/ACC 2004 guideline [25], in an inadequate
dose regimen demonstrated by Nascimento et al. [12], and the
economic impact of prolonged hospitalization, morbidity and
mortality related to deep sternal wound infection is much more
important than the small variation in cost due to the shortening
of the interval [6]. However, it is necessary to compare in a ran-
domized study this new, proposed dose regimen with that
tested in this study, with patients submitted to CPB only, calcu-
lating the sample size also to ﬁnd the incidence of adverse
effects with the increased total dose.
Cefuroxime is a water-soluble antibiotic, with good tissue
penetration and rapid distribution from plasma to tissue and
without accumulation in fat tissues [18]. Its elimination is
dependent on renal function with a minimal dose-limiting tox-
icity, so there are no recommendations to administer cefuroxime
by weight in adults [13, 14, 20]. It is necessary to emphasize that
the exclusion criteria excluded patients with a BMI of >35 kg/m2,
serum creatinine ≥1.4 mg/dl or previous nephrectomy.
Although this study focused on cefuroxime plasma concentra-
tions, it is necessary to report that no patient presented with a
surgical site infection. This ﬁnding can be justiﬁed by our sample
size and our allocation criteria, which excluded patients with
high-risk factors for infections (e.g. being elderly, obesity, dia-
betes mellitus, renal insufﬁciency).
In conclusion, CPB did not inﬂuence cefuroxime plasma con-
centrations, and a 1.5 g bolus of cefuroxime at anaesthesia
induction guaranteed plasma concentrations greater than four
times the MIC during the intraoperative period, which shows
that the extra bolus after CPB is unnecessary. However, the pro-
posed dose regimen was not satisfactory for the postoperative
period and might not be sufﬁcient for prolonged surgeries. The
dosing regimen for prophylaxis in patients undergoing coronary
surgery should be re-evaluated, using an interval between doses
of <6 h.
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